Skip to content

24/7 dementia helpline 800-272-3900

Dementia Today

Parkinsonian worms may hold the key to identifying drugs for Parkinson’s disease

Dementia TodayPublished November 11, 20115 min read

Key points

  • Researchers at The University of Texas at Austin have devised a simple test, using dopamine-deficient worms, for identifying drugs that may help people with Parkinson’s disease.
  • The test is based on the difficulty that these “parkinsonian” C. elegans worms have in switching from swimming to crawling when they’re taken out of water.
  • Pierce-Shimomura led a team of researchers, including Andres Vidal-Gadea, Stephen Topper and Layla Young, to identify this “motor switching” problem.
  • To identify potential therapeutics, Pierce-Shimomura begins with worms that have been mutated to be deficient in producing dopamine.

Researchers at The University of Texas at Austin have devised a simple test, using dopamine-deficient worms, for identifying drugs that may help people with Parkinson’s disease.

The worms are able to evaluate as many as 1,000 potential drugs a year. The researchers have received federal funding that could increase that to one million drug tests a year.

The test is based on the difficulty that these “parkinsonian” C. elegans worms have in switching from swimming to crawling when they’re taken out of water.

“They can crawl fine,” says Jon Pierce-Shimomura, assistant professor of neurobiology. “They go into a puddle and can swim fine. But as soon as the puddle goes away they crash. In some cases an individual will remain rigid for about a half hour.”

Pierce-Shimomura led a team of researchers, including Andres Vidal-Gadea, Stephen Topper and Layla Young, to identify this “motor switching” problem. Their findings were published last month in the Proceedings of the National Academy of Science.

“We take these motor transitions for granted,” says Pierce-Shimomura, “like getting up out of a chair or walking through a doorway from one surface to another. But people with Parkinson’s have a terrible time with this. They freeze at the threshold. It looks like we have a very simple worm model for this now.”

To identify potential therapeutics, Pierce-Shimomura begins with worms that have been mutated to be deficient in producing dopamine. It’s the loss of dopamine-producing cells in the brain that causes Parkinson’s disease in humans.

The dopamine-deficient worms are put through the same paces that lead to the immobility, but in the presence of a drug.

Key Facts
Around 6.3 million people worldwide have PD, with no differentiation for race or culture.
Parkinson’s disease (PD) is a chronic and progressive neurological disorder.
Individuals with PD experience difficulties with movement including shaking, stiffness, slow movements and problems with balance.
There is no cure for PD, and at present, no disease modifying therapies – current treatment focuses on symptom management.

If they become immobile as they normally would when water is removed, the researchers move on to the next drug. But if somehow a drug helps the worms’ brains overcome the dopamine deficiency and they transition to crawling, the lab has a potential therapeutic.

Pierce-Shimomura says that although humans have a vastly more complex nervous system than the worms, the two species share an “ancient and conserved” genetic structure to their dopaminergic systems. What works to overcome a dopamine deficiency in the worms may do something similar in humans, and it can be tested in worms with extraordinary speed.

Pierce-Shimomura has already begun testing potential drugs for Parkinson’s. So far he’s found one compound that shows promising effects in the worms. The particular compound has already been approved for use in humans for treatment of another condition.

The main symptoms of Parkinson’s disease are:

tremor, shaking, or trembling
slowed movement
stiff or rigid arms, legs, and trunk
balance trouble that can lead to falls

Tremors only appear at rest and not when the person is making purposeful movements. Later, the arms and legs may be affected. About 15% of people with Parkinson’s don’t have tremors; rather, they find their limbs or other areas turning stiff or rigid. Most people, however, have both. The rigidity becomes worse as the disease progresses, making movement difficult.

Slowed movement is another symptom of Parkinson’s disease. People may also experience trouble starting movement (e.g., starting to walk) and will move much slower than normal. When balance reflexes become impaired, it makes it difficult to turn quickly or negotiate narrow corners and doorways.

Working with the university’s Office of Technology Commercialization, he’s filed a patent application for the worm model for testing of neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

About half a million Americans suffer from Parkinson’s disease, a degenerative disorder of the central nervous system. Early symptoms of the disease include shaking, rigidity, and slowness of movement. As it progresses, the physical symptoms can advance to the point of incapacity, and cognitive impairments, including early dementia, can arise as well.

A huge barrier to preventing or treating diseases such as Parkinson’s is the amount of time it takes to identify drugs that work effectively. Typically, drugs are tested on mice – a process that is expensive and requires one to two years for mice to age while testing just a few dozen drugs at a time.

With the help of a few undergraduates Pierce-Shimomura believes that he can test about 1,000 drugs a year. The number could rise to one million a year if the process can be automated.

He recently received a competitive $3 million Transformative Research Projects Award from the National Institutes of Health with mechanical engineering professor Adela Ben-Yakar, to develop just such an automation process for parkinsonian worms as well as worms mutated to have other neurodegenerative diseases, including a C. elegans version of Alzheimer’s.

“These worms are so simple to work with, we can do these drug screens at massive scale,” says Pierce-Shimomura. “Right now the more hands we have, the more targets we can test.”

###

Daniel Oppenheimer
oppenheimer@austin.utexas.edu
512-745-3353
University of Texas at Austin

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. If a person with dementia is missing, injured or in danger, call 911 or your local emergency number.

Filed underDementia News

Worried about memory changes?

Normal aging, or an early warning sign?

Ten common changes, each set beside what is typical with age. Tick what you have noticed and see what to do next.

Open the 10-sign checklist

Getting help

Sudden changes are not just the dementia.

Dementia usually changes slowly. A sharp change over hours or days can mean an infection, delirium, a stroke or a medication problem, and needs a doctor the same day. Call 911 or your local emergency number if you see any of these:

  • Confusion that comes on suddenly, over hours or days
  • Face drooping, arm weakness or slurred speech
  • A fall, a head injury or new severe pain
  • Very drowsy or hard to wake

The free Alzheimer’s Association Helpline answers questions about memory loss, diagnosis and caregiving, day and night, in more than 200 languages (US).

If someone with dementia is missing

  1. STEP 115 minSearch close by firstCheck the house, garden, car and the places the person often walks to. Don’t spend longer than about 15 minutes.
  2. STEP 2911Then call for helpTell the operator the person has dementia and is a vulnerable adult. Police treat this as urgent.
  3. STEP 3PhotoHave details readyA recent photo, what they were wearing, medical conditions and places they used to live or work.

Based on Alzheimer’s Association guidance on wandering. Outside the US, call your local emergency number.